Precision Solutions

• 
  Advances in Bispecific and Trispecific Antibodies for Cancer Immunotherapy: Mechanisms, Clinical Progress, and Future Prospects

  Bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) represent a significant evolution in cancer immunotherapy. By simultaneously targeting two or three antigens, these multispecific antibodies enable precise immune cell redirection, overcome tumor heterogeneity and antigen escape, and enhance anti-tumor efficacy. With over 17 BsAbs now approved—primarily for hematologic malignancies—and trispecific candidates showing promising early clinical results (such as high response rates in relapsed/refractory multiple myeloma with favorable safety), this field is rapidly advancing. This article reviews their mechanisms, key clinical candidates, current challenges, and future prospects in both blood cancers and solid tumors.

• 
  Bispecific Antibody Custom Development — 15+ Formats, >90% Success Rate

  AtaGenix provides end-to-end bispecific antibody custom development supporting 15+ formats (BiTE, IgG-like, Fab-based, nanobody-based, multispecific). >90% project success rate using proprietary HEK293 and XtenCHO™ expression platforms. Full workflow from gene synthesis and vector construction to expression, purification, and QC (SDS-PAGE, SEC-HPLC, ELISA) in 5–6 weeks. Case studies include anti-EBV gH/gL and anti-GPC3×CD3E bispecific antibodies.